CARES-005, EMERALD-1, LEAP-012, TALENTACE: Pooled Analysis of HCC Treatment Trials

Tonggang Zhou's pooled analysis of four randomized controlled trials (CARES-005, EMERALD-1, LEAP-012, TALENTACE) compares the addition of PD-1/PD-L1 inhibitors and anti-VEGF drugs to transarterial chemoembolisation for unresectable, non-metastatic hepatocellular carcinoma. The analysis includes data from 1,431 patients, assessing endpoints like overall survival, progression-free survival, tumor response, and adverse events. The dataset was last updated on 2026-05-25.

Use Cases

• Compare progression-free survival rates between combination therapy and standard treatment based on hazard ratios.
• Analyze the incidence of grade 3-4 adverse events associated with the combination therapy.
• Evaluate objective response rates using RECIST and mRECIST criteria.
• Perform subgroup analyses to identify patient populations with consistent treatment benefits.
• Assess treatment discontinuation reasons (adverse events vs. disease progression) at data cutoff.

Strengths

• Data is derived from four randomized controlled trials, a rigorous study design.
• Analysis includes 1,431 patient records, providing a substantial sample size.
• Endpoints are assessed using both RECIST version 1.1 and mRECIST criteria.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (31.5 KB), indicating limited scope or summary-level data.

Provenance

Source

Tonggang Zhou

Collection Method

Pooled analysis of four RCTs identified via systematic search of six databases.

Freshness

Last updated 2026-05-25 13:05:30; freshness should be verified.